“We have created one of the world’s largest database of toxicology data”
Manuel Pastor, head of the PharmacoInformatics group of GRIB, talks about the European eTOX project, in which they have managed to get several pharmaceutical companies to share their toxicology data.
eTOX is a European project funded by the Innovative Medicines Initiative (IMI), which aims to promote the development of new drugs, especially in areas where there are unmet medical or social needs. In this case, the project focuses on drug toxicology. "The value of the eTOX project is to create a culture of collaboration among different pharmaceutical companies, an efficient way to use the information that they generate in a field as important as the toxicology", explains Pastor.
Read the full interview at the last edition of el·lipse magazine
5th EU-ToxRisk General Assembly Meeting & 2nd Industry Stakeholder Meeting in February 2019
The european project EU-ToxRisk: "an integrated european 'flagship' program driving mechanism-based toxicity testing and risk assessment for the 21st century" is a H2020 supported collaborative project for the period 2016-2021 in which academia joins forces with small and medium-sized enterprises (SMEs), large industry, contract research organisations (CROs) and regulatory bodies to achieve a paradigm shift in toxicology towards a more efficient and animal-free chemical safety assessment. The GRIB takes part of this project as coordinator of WP4.
From 12-14 Feb. 2019, the EU-ToxRisk project hold its 5th General Assembly (GA) meeting, together with its 2nd Industry Stakeholders Meeting. This year's edition also took place in Egmond aan Zee, Netherlands. Altogether, some 120 people - including project members, advisory board members and external industry stakeholders - attended the event which was very successfull with interesting presentations, fruitful discussions, and instructive poster sessions.
FAIRPlus
The project FAIRPlus aims to improve data management and data governance in European health research. The project aims to increase the discovery, accessibility and reusability of data from selected projects funded by the EU's Innovative Medicine Initiative (IMI), and internal data from pharmaceutical industry partners. It will also organise training for data scientists in academia, SMEs and pharmaceutical companies to enable wider adoption of best practises in life science data management. The project is funded by the Innovative Medicines Initiative (IMI2) together with the pharmaceutical industry for the period 2019-2021.
- Puigdevall P, Piccari L, Blanco I, Barbera JA, Geiger D, Badenas C, Mila M, Castelo R, Madrigal I. Genetic linkage analysis of a large family identifies FIGN as a candidate modulator of reduced penetrance in heritable pulmonary arterial hypertension. J Med Genet, 2019
DOI: 10.1136/jmedgenet-2018-105669. - Reixachs-Sole M, Ruiz-Orera J, Alba MM, Eyras E. Ribosome profiling at isoform level reveals an evolutionary conserved impact of differential splicing on the proteome. bioRxiv, 2019 DOI: 10.1101/582031.
- Viktoria Szabo. Polypharmacy in the elderly: data, models, and strategies. Universitat Pompeu Fabra. March 13rd, 2019. Thesis Director: J Mestres
- Aguirre-Plans J, Piñero J, Sanz F, Furlong LI, Fernandez-Fuentes N, Oliva B, Guney E. GUILDify v2.0: A tool to identify molecular networks underlying human diseases, their comorbidities and their druggable targets. J Mol Biol, 2019. pii: S0022-2836 (19) 30117-2.. PMID: 30851278 . DOI: 10.1016/ j.jmb.2019.02.027.
Research
groups
